Published On: Wed, Oct 19th, 2016

Upgrades And Downgrades For Juno Therapeutics, Inc. (NASDAQ:JUNO)


Recently stock market analysts have updated their consensus ratings on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO).

Most recent broker ratings

10/13/2016 – Juno Therapeutics, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 61 price target on the stock.

09/27/2016 – Juno Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 45 price target on the stock.

09/08/2016 – Juno Therapeutics, Inc. had its “sell” rating reiterated by analysts at BTIG Research. They now have a USD 23 price target on the stock.

08/05/2016 – Juno Therapeutics, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 50 price target on the stock.

07/11/2016 – Juno Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 51 price target on the stock.

07/08/2016 – Juno Therapeutics, Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 35 price target on the stock.

07/08/2016 – Juno Therapeutics, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 39 price target on the stock.

06/02/2016 – Raymond James began new coverage on Juno Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 52 price target on the stock.

04/20/2016 – Juno Therapeutics, Inc. had its “buy” rating reiterated by analysts at SunTrust. They now have a USD 50 price target on the stock.

02/25/2016 – Citigroup began new coverage on Juno Therapeutics, Inc. giving the company a “buy” rating.

02/17/2016 – Juno Therapeutics, Inc. was upgraded to “buy” by analysts at Guggenheim.

12/15/2015 – Juno Therapeutics, Inc. was upgraded to “buy” by analysts at Standpoint Research.

11/18/2015 – Goldman Sachs began new coverage on Juno Therapeutics, Inc. giving the company a “neutral” rating.

07/22/2015 – Northland Securities began new coverage on Juno Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 64 price target on the stock.

06/30/2015 – Juno Therapeutics, Inc. had its “equal weight” rating reiterated by analysts at Morgan Stanley.

Juno Therapeutics, Inc. has a 50 day moving average of 29.37 and a 200 day moving average of 35.63. The stock’s market capitalization is 2.82B, it has a 52-week low of 22.37 and a 52-week high of 57.82.

The share price of the company (NASDAQ:JUNO) was up +2.06% during the last trading session, with a high of 27.98 and the volume of Juno Therapeutics, Inc. shares traded was 1106444.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.